Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of September, 2009
Commission File Number 0-28564
QIAGEN N.V.
(Translation of registrant’s name into English)
Spoorstraat 50
5911 KJ Venlo
The Netherlands
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- .
Table of Contents
Form 6-K
TABLE OF CONTENTS
| Item |
Page | |
| 3 | ||
| 4 | ||
| 5 | ||
2
Table of Contents
On September 29, 2009, QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) (“QIAGEN”) announced that the underwriters for its offering of 27.5 million newly issued common shares (the “Offering”) have exercised in full their over-allotment option to purchase 4,125,000 common shares (the “Additional Shares”), and QIAGEN will issue the Additional Shares at the price for the Offering, as previously announced, of US$ 20.25 per share (EUR 13.82). The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
3
Table of Contents
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
QIAGEN N.V.
By: /s/ Roland Sackers
Roland Sackers
Chief Financial Officer
Date: September 30, 2009
4
Table of Contents
| Exhibit No. |
Exhibit | |
| 99.1 | Press Release issued September 29, 2009 | |
5
Table of Contents
Exhibit 99.1
Contact: IR QIAGEN; email: ir@qiagen.com; phone: +49 2103 29 11710
(Ad-hoc notification pursuant to Section 15 of the German Securities Trading Act)
QIAGEN Announces Exercise In Full of Over-Allotment Option by Underwriters in Offering of New Common Shares
Venlo, the Netherlands – September 29, 2009, QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Stock Exchange, regulated market (Prime Standard): QIA) (the “Company”) announces that the underwriters for its offering of 27.5 million newly issued common shares (the “Offering”) have exercised in full their over-allotment option to purchase 4,125,000 common shares (the “Additional Shares” and, together with the 27.5 million common shares, the “Shares”), and the Company will issue the Additional Shares at the price for the Offering, as previously announced, of US$ 20.25 per share (EUR 13.82).
The exercise of the over-allotment option brings the total number of common shares to be sold by QIAGEN in the Offering to 31,625,000. Gross proceeds of the Offering (including the Additional Shares) are expected to be approximately US$ 640 million (EUR 437 million).
The Company plans to use the net proceeds of the Offering to fund the acquisition of DxS Ltd. announced on September 22, 2009 and potential future acquisitions, to strengthen its balance sheet and for general corporate purposes.
Deutsche Bank, Goldman Sachs International and J.P. Morgan acted as Joint Global Coordinators and Joint Bookrunners of the Offering.
QIAGEN N.V.
Spoorstraat 50
5911 KJ Venlo
The Netherlands
ISIN: NL 0000240000
German Securities Identification Number (WKN): 901626
Common Code: 007994915
This ad-hoc notification does not constitute, or form part of, an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for, securities and any subscription for or purchase of, or application for, the Shares should only be made on the basis of information contained in the prospectuses (the “Prospectuses”) prepared by the Company in connection with the Offering. In particular, any subscription for or purchase of, or application for, the Shares in the United States should only be made on the basis of information contained in the prospectus, including the prospectus supplement forming a part of the automatically effective shelf registration statement in connection with the Offering.
1
Table of Contents
The Company has filed a registration statement in the United States under the U.S. Securities Act of 1933, as amended (the “Securities Act”), in connection with the offer and sale of the Shares. A written prospectus, including the prospectus supplement, satisfying the requirements of Section 10 of the Securities Act and containing the detailed terms of the Offering is available on the U.S. Securities and Exchange Commission’s website at www.sec.gov.
This ad-hoc notification does not constitute a recommendation. Prospective investors should consult a professional advisor as to the suitability of the Shares for the individual concerned. All investments are subject to risk. The value of the Shares may fluctuate. An investment in the Company is speculative and involves a substantial degree of risk, including the risk of total loss of such investment.
Prospective investors should not treat the contents of this document as advice relating to legal, taxation or investment matters, and are to make their own assessments concerning these and other consequences of any investment, including the merits of investing and the risks. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision.
This ad-hoc notification does not constitute, and may not be used for the purposes of, an offer or an invitation to subscribe for the Shares by any person in any jurisdiction in which (i) such offer or invitation is not authorised; or (ii) in which the person making such offer or invitation is not qualified to do so; or (iii) to any person to whom it is unlawful to make such offer or invitation.
The distribution of this ad-hoc notification in certain jurisdictions may be restricted by law, and therefore persons into whose possession this ad-hoc notification comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdiction.
The content of this ad-hoc notification includes statements that are, or may be deemed to be, “forward-looking statements” based on management’s expectations, including, but not limited to, statements relating to the proposed Offering and the expected use of the proceeds from the Offering. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company’s actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
This document is an advertisement for the purposes of applicable measures implementing Directive 2003/71/EC (such Directive, together with any applicable implementing measures in the relevant home Member State under such Directive, the “Prospectus Directive”). A prospectus for the purpose of the listing of the Shares on the regulated market (Prime Standard segment) of the Frankfurt Stock Exchange was approved by the AFM and published on September 24, 2009 by being made available to the public, free of charge, in printed form at the registered office of QIAGEN N.V., Spoorstraat 50, 5911 KJ Venlo, the Netherlands, fax: (+31)-77-320-8409; email: ir@qiagen.com and through the offices of the Joint Global Coordinators.
In any EEA Member State that has implemented the Prospectus Directive, this communication is only addressed to and directed at qualified investors in that Member State within the meaning of the Prospectus Directive.
This communication is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Shares will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. ###
2